For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Opdivo’s Fulminant Type 1 Diabetes Risk Re-Stressed in MHLW Safety Bulletin
April 20, 2016
- LDP Finalizes Proposal for Growth Strategy; Touches on CIN, Drug Discovery Seeds
April 20, 2016
- Sales Reps Top Source of Drug Safety Information for Both Clinics and Pharmacies: PMDA Survey
April 19, 2016
- Wholesalers Cited Urgent Deliveries as Major Concern: Ryukaikon
April 19, 2016
- Wholesalers’ Negative Primary Margins on Sales Level Off: Ryukaikon
April 18, 2016
- PMDA Had 58 Paid Advisory Sessions on Drug Development for Startups, Academia: FY2015
April 18, 2016
- Ryukaikon Agrees on Mandatory Barcode Labeling by March 2021; March 2022 for Exceptions
April 18, 2016
- Quake Brings Production Offline at 1 Out of 24 Firms in Affected Region: MHLW
April 18, 2016
- Promoting Use of Patient Registries Important in Building Clinical Innovation Network: Health Policy Bureau Chief
April 18, 2016
- Dyslipidemia Risk Triples in Patients on Olanzapine: PMDA Epidemiology Study
April 15, 2016
- Expedited Review Systems Now in Place in 3 Major Markets, but How Are They Different?
April 15, 2016
- LDP Proposal for New Growth Strategy to Push “Clinical Innovation Network”
April 15, 2016
- New Scheme on Switch OTC Gets Underway
April 14, 2016
- MHLW to Issue Notification to Ensure Restricted Use of Repatha
April 14, 2016
- Indication-Based Front-Loaded Re-Pricing, Coverage Limits Emerge for Pricey Meds: Chuikyo
April 14, 2016
- Chuikyo to Make Go or No-Go Decision on Drug Price Survey by Mid-2016
April 14, 2016
- MHLW Panels Approve Guidelines for Reporting Adverse Reactions to Hep B Vaccines
April 14, 2016
- Govt, Industry Agree to Boost Public-Private Policy “Dialogue” to Deepen Talks on Social Security Challenges
April 13, 2016
- Chuikyo OKs Repatha for NHI Price Listing on April 20, Peak Sales Projected at 49 Billion Yen
April 13, 2016
- MHLW Advisory Panel to Discuss Ono’s Cancer Drug Carfilzomib on April 25
April 12, 2016
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…